To assess the impact of comorbidities on long-term all-cause mortality in patients hospitalized with exacerbated signs/symptoms of previously chronic stable HF (AE-CHF). Methods: 1119 patients admitted for AE-CHF and with NT-proBNP levels N900 pg/mL were enrolled. Univariable and multivariable Cox analyses were performed to assess the association of age, gender, hypertension, diabetes, obesity, atrial fibrillation, coronary heart disease (CHD), chronic obstructive pulmonary disease, previous cerebrovascular accidents, chronic liver disease (CLD), thyroid disease, renal impairment (RI), and anemia with 3-year all-cause mortality. Results: During the follow-up, 441 patients died and 126 underwent heart transplantation (HT) or ventricular assist device (VAD) implantation. 45.8% of the fatal events and 52.4% of HT/VAD implantations occurred within 180 days after admission. Increasing age (p = .012), obesity (p = .037), atrial fibrillation (p = .030), CHD (p = .015), CLD (p = .001), RI (p b .001), and anemia (p b .001) were independently associated with 3-year all-cause mortality. Most of the prognostic impact of CHD, took place within the first 180 days after admission. Male gender was associated with mortality beyond 180 days. Compared with normal weight, obesity was associated with better overall survival. Obese patients, however, had significantly lower NT-proBNP concentrations and less frequently presented with hypotension, hyponatremia, and severe left ventricular systolic dysfunction, despite a similar prevalence of severe dyspnea at admission. Conclusions: Several comorbidities are associated with long-term risk of death in hospitalized patients with worsening HF, although the nature of this association does appear to be complex. Our data may help to raise awareness about the clinical relevance of comorbid conditions.
More than one million admissions for heart failure (HF) occur annually both in the United States and Europe [1, 2] , most patients being cared for by noncardiologist physicians [3] . Roughly 80% of admissions are attributable to acute exacerbation of chronic HF (AE-CHF) [4, 5] . Hospitalization marks a downward trajectory of HF [6] . Despite a slight decline in risk-adjusted 1-year mortality over time [7] , prognosis of hospitalized HF remains grim, with 6-month and 1-year mortality rates of approximately 20% and 30%, respectively [1, 4, 5, 8] , with progressive HF being the most common cause of death [6] . Although the greatest risk is in the first months, hospitalization still confers a 2-fold greater risk of death after 2 years after admission compared with not hospitalized HF [5, 6] .
It is generally assumed that comorbidities are common in HF and associated with increased mortality and morbidity risk, increased complexity of clinical management, multidrug regimens often difficult to adhere to, increased disability and poor quality of life, and high health care resource utilization [9, [10] [11] [12] . In chronic HF, a wide spectrum of comorbidities has been carefully studied [13, 14] . In acute HF, the clinical relevance of renal impairment (RI) and anemia also has been well characterized [2, 15] . However, information about additional important comorbidities is limited [11, [15] [16] [17] , with only few studies systematically addressing the impact of such comorbidities on mortality risk [18] [19] [20] . Interestingly, some data suggest a differential predictive value of comorbidities depending on the time horizon of risk prognostication European Journal of Internal Medicine xxx (2016) xxx-xxx [18, 20] . Because of this gap in evidence, the implications of comorbidities for the care and management of acute HF patients, with few exceptions, could not be adequately addressed in disease-specific guidelines [15, 11] .
Hospital clinicians are strongly oriented toward the index disease [21] . Defining the prognostic role of comorbidities in acute HF might help to raise awareness about the clinical relevance of comorbid conditions among clinicians and care-givers, to improve assessment of patients' vulnerability, and to inform decision making about postacute referrals and management [21] [22] [23] . In the present study, we investigated the impact of comorbidities and their time-dependent influence on long-term all-cause mortality in hospitalized patients with AE-CHF.
Methods
This was a retrospective multicenter study. Four Cardiology Centers participated in the study. The study population consisted of 1119 patients admitted for AE-CHF between April 1, 2006 and November 30, 2014. Patients were eligible if they fulfilled the following selection criteria. Inclusion criteria were: current hospitalization for worsening signs and symptoms of previously chronic stable HF, history of HF of at least 1 year, chronic treatment with standard therapies, and NT-proBNP concentrations N900 pg/mL at admission. Exclusion criteria were: "de novo" acute HF; cardiogenic shock; acute HF listed as a secondary discharge diagnosis, developed after admission for another admitting diagnosis, or due to acute myocarditis or restrictive cardiomyopathy; acute coronary syndromes; recent (b3 months) cardiac surgical or percutaneous procedures; planned coronary revascularization; congenital heart disease; stenotic valvular disease; and NT-proBNP concentrations ≤900 pg/mL at admission. Clinical and laboratory data were collected at admission. Left ventricular ejection fraction (LVEF) was assessed by two dimensional echocardiography early during hospitalization.
The primary outcome was all-cause mortality within 3 years after admission. Survival status was ascertained by linking with the Health Regional Information Systems or by telephone follow-up. The study was approved by the Institutional Review Board.
Statistical analysis
Data are reported as means and standard deviations or medians and 25th and 75th percentiles for continuous variables or percentages of patients for categorical variables. We performed univariable and multivariable Cox regression analyses to identify the comorbidities associated with 3-year all-cause mortality. The following covariates were considered: hypertension; diabetes mellitus; obesity (body mass index [BMI] ≥ 30 kg/m 2 ); atrial fibrillation; coronary heart disease (CHD); chronic obstructive pulmonary disease; previous cerebrovascular accidents; chronic liver disease (CLD); thyroid disease; renal impairment (RI); and anemia. Body mass index was categorized as follows: b 20, 20-24.9 (referent), 25-29.9, ≥30 kg/m 2 . Renal impairment was defined as an estimated glomerular filtration rate (eGFR) b60 mL/min/1.73m 2 ; anemia as hemoglobin b 12 g/dL [24] ; CHD as having a documented history of myocardial infarction, percutaneous coronary angioplasty, or coronary artery bypass grafting. The other comorbidities were diagnosed on the basis of medical history and previous relevant documentation from inpatient or outpatient records and/or appropriate medical treatment. Candidate comorbidities associated with the primary outcome with p ≤ 0.10 at univariable analysis were retained for inclusion in the multivariable analysis. Gender was forced into the final model. The patients who underwent heart transplantation (HT) or ventricular assist device (VAD) implantation during the follow-up were censored at the time of the event. Hazard ratios and 95% confidence intervals (CI) were computed. As an explanatory analysis, we also investigated the association of the comorbidities found to be significant in the initial multivariable analysis with early (from admission to 180 days) and late (181 days to 3 years) mortality using Cox proportional hazards modeling. The analysis assessing the association with late mortality was conditional on being alive at 180 days. The cut-point of 180 days was chosen because the risk of death is greatest in the first 6 months [6] . Finally, the association of baseline variables with comorbid burden was assessed using multivariable logistic regression analysis. Odds ratio (OR) with 95% CIs were calculated.
Analyses were conducted using STATA software, version 12 (StataCorp LP, College Station, Tex).
Results
Of the 1119 patients, 82 were excluded because of missing values for BMI and 11 were lost to follow-up, leaving 1026 patients available for analysis. Baseline characteristics are reported in Table 1 .
During the 3-year follow-up, 441 patients (42.9%) died and 126 (12.3%) underwent HT or VAD implantation. Fig. 1 shows cumulative survival free of HT/VAD implantation. 45.8% of the fatal events (N = 202) and 52.4% (N = 66) of HT/VAD implantations occurred within 180 days after admission. The Kaplan-Meier estimated cumulative incidence of death at 3 years was 53% (95% CIs: 49-56). The results of univariable and multivariable Cox analyses are reported in Tables 2 and 3 (Table 3) . When Center was included in the multivariable model as a stratification variable, statistical significance of age did not hold. The prognostic impact of RI, anemia, and CLD was consistent across the two time periods while that of age, gender, and CHD was dependent on the time-horizon of risk prognostication (Table 3) A secondary analysis was performed to assess the strength and magnitude of the association between comorbidities and outcome in patients stratified by LVEF or NT-proBNP. The results are reported in supplemental 
Discussion
There are three major findings of this study: 1) RI, anemia, CLD, and atrial fibrillation were independent predictors of 3-year all-cause mortality; no time-dependent asymmetry in their predictive value was observed; 2) the impact of age, gender, and CHD on mortality risk did appear to be time-dependent, with most of their prognostic impact on mortality taking place within the first 6 months or thereafter; and 3) high comorbid burden was strongly correlated with increasing age; no correlation with indices of HF severity was observed.
Renal impairment, anemia, CLD, and atrial fibrillation were independently associated with an increased risk of dying within 3 years. Renal impairment increased the risk by 12% for each 5-unit decrease below 60 mL/min/1.73 m 2 , anemia by 54%, and CLD by 74%. No timedependent asymmetry in their predictive value was observed. Atrial fibrillation conferred a 24% increased risk of overall mortality; the excess risk of early and late mortality was of similar magnitude, albeit with wider confidence intervals. Multiple studies, most of which had however a time-horizon of less than 1 year, have investigated the prognostic role of RI, anemia, and atrial fibrillation in acute HF. These studies consistently demonstrated that RI, anemia, and atrial fibrillation are powerful predictors of adverse outcomes [9, 15] . Conversely, the prognostic impact of CLD in acute HF has been scarcely investigated. In the Enhanced Feedback for Effective Cardiac Treatment (EFFECT) study, CLD was independently associated with increased 30-day and 1-year mortality [25] . Our findings add to the existing knowledge by showing that the impact of RI, anemia, CLD, and atrial fibrillation extends up to 3 years. Coronary heart disease significantly contributed to mortality risk. Most of the prognostic impact of CHD, however, took place within the first 6 months after admission with a 46% increased risk of death. Several lines of evidence point to an active role of coronary ischemia in patients with acute HF and CHD. Epidemiologic studies indicate that acute coronary ischemia is a common precipitant of HF exacerbation requiring hospitalization and is associated with increased in-hospital and 90-day mortality [15, 26, 27] . Autopsy studies showed that acute coronary findings, including clinically unrecognized acute myocardial infarction, are not infrequent in patients died from HF [28, 29] . Moreover, as reported by Beohar et al. [30] exhaustion of the mechanisms of coronary autoregulation may contribute to compromise coronary perfusion in acute HF and CHD, making the myocardium particularly vulnerable to decreased perfusion pressure and/or increased demand. In a study of 8772 patients with acute HF, ST segment depression at presentation was associated with increased 30-day mortality primarily among patients with ischemic HF, [31] . Notably, the frequency of elevated troponin values in patients with ST-segment depression was N2-fold higher than in those without ST-segment depression. Release of cardiac troponin, reflecting myocardial injury or death, is prevalent in acute HF and is associated with increased in-hospital and 180-day mortality, with higher levels being associated with CHD and higher mortality [32] [33] [34] . Although multiple potential mechanisms may contribute to troponin release in acute HF, coronary ischemia has been suggested as a primary contributor in patients with acute HF and CHD [34, 35] . Finally, in the OPTIMIZE-HF registry, "in-hospital angiography resulted in a significantly reduced risk of death within 90 days and higher rates of revascularization and uptake of evidence-based therapies in patients with ischemic HF" [36] . Collectively, these data underscore the potential importance of underlying CHD and associated coronary ischemia as a factor promoting exacerbation of HF and worsening short-term survival in acute HF. Increasing age exposed the patients to a higher risk for late mortality. The strong association of increasing age with comorbidities known to worsen short-term mortality [37] , however, may have weakened the strength of the association between increasing age and early mortality in multivariable modeling. Nonetheless, advanced age still influenced late mortality after adjusting for comorbidities. It is conceivable that the short life expectancy at older ages per se may have contributed to the increased risk of late mortality.
Consistent with previous studies, obese patients had better survival compared with normal-weight patients. Multiple mechanisms have been speculated to explain the inverse relationship between obesity and mortality risk in HF, including greater metabolic reserves, higher skeletal mass, lower adiponectine levels, decreased cathecolamine response to stress, and obesity as opposed to cardiac cachexia [38, 39] . The impact of these alterations on outcome of acute HF remains however speculative. The possibility that obese are less ill than normalweight patients also has been raised [38, 39] . Our study adds to the existing knowledge by showing that obese patients, despite a similar prevalence of severe dyspnea at presentation, not only have significantly lower NT-proBNP concentrations [38] , but also are less frequently hypotensive and hyponatremic and have lower prevalence of severe left ventricular systolic dysfunction compared with normal-weight patients. These findings suggest that obese patients present with less severe cardiac disease and a more favorable risk profile compared with normalweight patients, despite a similar degree of dyspnea. As stated by von Haehling [38] , "it is a truism that ill patients are ill and die early, but the reverse is true as well". Thus, the "protective" effect of obesity might merely reflect the higher risk for early death of nonobese patients.
Male gender significantly increased the risk of late mortality by 45%, after adjusting for age and significant comorbidities. The more benign progression of the myocardial remodeling process in women versus men, which is independent of age and menopause [40] , might be a modifier of long-term outcome in HF.
The analysis in subgroups of patients stratified by LVEF or NTproBNP suggests that the degree of left ventricular systolic function and the levels of NT-proBNP may modulate the strength and magnitude of the association of comorbidities with long-term prognosis, underscoring the high level of complexity of this association. However, it must be emphasized that, because of the low number of patients with LVEF ≥40% and resultant reduced power and wide confidence intervals, the analysis of this group was limited. These issues need further investigation.
Limitations
The limitations of studies investigating the prognostic role of comorbidities have been pointed out [20, 25] . Some limitations of the present study should be acknowledged. As with most prognostic studies in HF, the present study was retrospective. Other unmeasured or not documented comorbidities, such as for example frailty, cognitive impairment, and depression, may have influenced actual mortality risk. Underreporting in medical records is another possible limitation. Compared with patients enrolled in administrative database, our patients were younger and more frequently males. Although enrollment in cardiology wards may have been a contributing factor [41, 42] , this feature needs be recognized as a limitation. Advancing age, indeed, was a powerful driver of increasing comorbid burden. Body mass index assessment has inherent limitations for defining overweight/obesity [43] ; moreover, BMI may be influenced by intensive diuretic therapy. Data were derived from a cohort of patients with AE-CHF; this may limit the generalizability of the results. Nonetheless, AE-CHF accounts for approximately 80% of all admissions for acute HF and is burdened with a worse prognosis compared with de novo HF [4, 5, 24] . Most patients had left ventricular systolic dysfunction. This finding, however, is consistent with previous observations that patients with AE-CHF have lower LVEF compared with de novo acute HF [44] . We focused on mortality; from patient perspective, quality of life also ranks high in importance.
Conclusions
Assessment of comorbid conditions is recommend by diseasespecific guidelines [15] . We showed that several comorbidities shorten life expectancy of hospitalized patients with AE-CHF. Our data may help to raise awareness about the clinical relevance of comorbid conditions among clinicians, to improve assessment of patients' vulnerability, to inform decision making about post-acute referrals and management, and to identify patients at high risk of death. In patients with a high comorbid burden, a multidisciplinary approach may be most appropriate and efficacious strategy to deliver holistic care [45] . 
